JP6168673B2 - アリールアルキルアミン化合物含有医薬組成物 - Google Patents

アリールアルキルアミン化合物含有医薬組成物 Download PDF

Info

Publication number
JP6168673B2
JP6168673B2 JP2016197725A JP2016197725A JP6168673B2 JP 6168673 B2 JP6168673 B2 JP 6168673B2 JP 2016197725 A JP2016197725 A JP 2016197725A JP 2016197725 A JP2016197725 A JP 2016197725A JP 6168673 B2 JP6168673 B2 JP 6168673B2
Authority
JP
Japan
Prior art keywords
weight
parts
pharmaceutical composition
composition according
excipient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016197725A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017071599A (ja
Inventor
村 信 爾 谷
村 信 爾 谷
井 宏 子 吉
井 宏 子 吉
田 見 二 岩
田 見 二 岩
澤 直 人 井
澤 直 人 井
田 元 洋 太
田 元 洋 太
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Priority to US15/766,426 priority Critical patent/US10350194B2/en
Priority to PCT/JP2016/080013 priority patent/WO2017061621A1/ja
Priority to EP16853772.8A priority patent/EP3360551A4/en
Priority to KR1020197019836A priority patent/KR102488488B1/ko
Priority to KR1020187012497A priority patent/KR102000897B1/ko
Priority to TW109133308A priority patent/TWI808349B/zh
Priority to CN201680058580.7A priority patent/CN108135883B/zh
Priority to TW105132660A priority patent/TWI708603B/zh
Publication of JP2017071599A publication Critical patent/JP2017071599A/ja
Application granted granted Critical
Publication of JP6168673B2 publication Critical patent/JP6168673B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2016197725A 2015-10-07 2016-10-06 アリールアルキルアミン化合物含有医薬組成物 Active JP6168673B2 (ja)

Priority Applications (8)

Application Number Priority Date Filing Date Title
PCT/JP2016/080013 WO2017061621A1 (ja) 2015-10-07 2016-10-07 アリールアルキルアミン化合物含有医薬組成物
EP16853772.8A EP3360551A4 (en) 2015-10-07 2016-10-07 PHARMACEUTICAL COMPOSITION WITH ALRYL ALKYLAMINE COMPOUND
KR1020197019836A KR102488488B1 (ko) 2015-10-07 2016-10-07 아릴알킬아민 화합물 함유 의약 조성물
KR1020187012497A KR102000897B1 (ko) 2015-10-07 2016-10-07 아릴알킬아민 화합물 함유 의약 조성물
US15/766,426 US10350194B2 (en) 2015-10-07 2016-10-07 Pharmaceutical composition containing an arylalkylamine compound
TW109133308A TWI808349B (zh) 2015-10-07 2016-10-07 含有芳基烷基胺化合物之醫藥組合物
CN201680058580.7A CN108135883B (zh) 2015-10-07 2016-10-07 含有芳基烷基胺化合物的药物组合物
TW105132660A TWI708603B (zh) 2015-10-07 2016-10-07 含有芳基烷基胺化合物之醫藥組合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015199694 2015-10-07
JP2015199694 2015-10-07

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016207285A Division JP2017071605A (ja) 2015-10-07 2016-10-21 アリールアルキルアミン化合物含有医薬組成物

Publications (2)

Publication Number Publication Date
JP2017071599A JP2017071599A (ja) 2017-04-13
JP6168673B2 true JP6168673B2 (ja) 2017-07-26

Family

ID=58538545

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016197725A Active JP6168673B2 (ja) 2015-10-07 2016-10-06 アリールアルキルアミン化合物含有医薬組成物
JP2016207285A Pending JP2017071605A (ja) 2015-10-07 2016-10-21 アリールアルキルアミン化合物含有医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016207285A Pending JP2017071605A (ja) 2015-10-07 2016-10-21 アリールアルキルアミン化合物含有医薬組成物

Country Status (6)

Country Link
US (1) US10350194B2 (enExample)
EP (1) EP3360551A4 (enExample)
JP (2) JP6168673B2 (enExample)
KR (1) KR102000897B1 (enExample)
CN (1) CN108135883B (enExample)
TW (2) TWI708603B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100800708B1 (ko) * 2001-09-27 2008-02-01 삼성전자주식회사 키 텔레폰 시스템의 포트 상태 진단 방법
CN108379588B (zh) * 2018-03-05 2024-07-02 合肥合源药业有限公司 托吡酯组合物
KR20210096162A (ko) * 2018-11-27 2021-08-04 쿄와 기린 가부시키가이샤 의약 조성물
EP4029867A1 (en) * 2021-01-13 2022-07-20 Alpha Cognition Inc. Solid forms of galantamine benzoate gluconate
CN115006363A (zh) * 2022-06-23 2022-09-06 上海信谊万象药业股份有限公司 一种牡蛎碳酸钙咀嚼片及其制备方法
CN115381094B (zh) * 2022-08-18 2023-10-24 河南中大恒源生物科技股份有限公司 一种低臭味水溶性叶绿素铜及其制备方法与应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4880457A (enExample) 1972-01-31 1973-10-27
JPS5547615A (en) * 1978-09-29 1980-04-04 Taiyo Yakuhin Kogyo Kk Stable solid drug of nifedipine
JP2914690B2 (ja) * 1989-12-13 1999-07-05 グレラン製薬株式会社 安定なビタミンｄ▲下３▼類含有製剤
JP2001233766A (ja) * 2000-11-15 2001-08-28 Ohara Yakuhin Kogyo Kk プラバスタチンナトリウムの錠剤
JP2003104887A (ja) * 2001-09-28 2003-04-09 Maruko Seiyaku Kk 光に安定なアラニジピン含有組成物
US7732474B2 (en) * 2002-08-02 2010-06-08 Ratiopharm, Gmbh Pharmaceutical preparation containing a benzimidazole compound mixed with microcrystalline cellulose and a method for its preparation
US20040122048A1 (en) * 2002-10-11 2004-06-24 Wyeth Holdings Corporation Stabilized pharmaceutical composition containing basic excipients
JP4018664B2 (ja) * 2003-04-30 2007-12-05 第一三共株式会社 安定化固形製剤
GB0316206D0 (en) 2003-07-10 2003-08-13 Glaxo Group Ltd Pharmaceutical formulation
TWI346114B (en) 2003-09-29 2011-08-01 Method for stabilization of diarylvinylene compounds
JP2005154431A (ja) * 2003-11-07 2005-06-16 Takeda Chem Ind Ltd 固形製剤
EP1682087A1 (en) 2003-11-07 2006-07-26 Takeda Pharmaceutical Company Limited Chewable tablet
JP4783573B2 (ja) * 2004-02-20 2011-09-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 ワルファリンカリウム含有医薬組成物とその製造方法
DK1744781T3 (da) * 2004-04-30 2012-10-15 Bkg Pharma Aps Behandling af infektionssygdomme
US8362274B2 (en) * 2004-05-28 2013-01-29 Mitsubishi Tanabe Pharma Corporation Arylalkylamine compound and process for preparing the same
JP2007032370A (ja) * 2005-07-25 2007-02-08 Aisin Seiki Co Ltd 電動ポンプ
US7563930B2 (en) 2005-11-22 2009-07-21 Teva Pharmaceutical Industries Ltd Crystal forms of Cinacalcet HCI and processes for their preparation
SI1880718T1 (sl) * 2006-07-10 2011-11-30 Pfleger R Chem Fab Farmacevtski pripravki za oralno dajanje z nadzorovanim sproščanjem zdravila v majhne intestinke kolone in postopek njihove priprave
GB0724478D0 (en) * 2007-12-14 2008-01-30 Karobio Ab Pharmaceutical compositions
US20110318417A1 (en) * 2008-12-08 2011-12-29 Actavis Group Ptc Ehf Highly pure cinacalcet or a pharmaceutically acceptable salt thereof
JP5591128B2 (ja) * 2009-01-29 2014-09-17 大日本住友製薬株式会社 内核を有する口腔内崩壊錠
BR112012014328B1 (pt) * 2009-12-16 2021-06-15 Basf Se Composição de revestimento de película, forma de dosagem fornecida com um revestimento de película, e, uso das composições de revestimento de película
JP6133009B2 (ja) 2010-08-11 2017-05-24 協和発酵キリン株式会社 トピラマート顆粒
KR102177643B1 (ko) 2013-09-05 2020-11-11 미쓰비시 타나베 파마 코퍼레이션 신규한 결정성 아릴알킬아민 화합물 및 그의 제조 방법

Also Published As

Publication number Publication date
US10350194B2 (en) 2019-07-16
EP3360551A1 (en) 2018-08-15
TWI808349B (zh) 2023-07-11
EP3360551A4 (en) 2019-07-31
CN108135883A (zh) 2018-06-08
JP2017071605A (ja) 2017-04-13
US20180296526A1 (en) 2018-10-18
TW201717937A (zh) 2017-06-01
TWI708603B (zh) 2020-11-01
JP2017071599A (ja) 2017-04-13
KR20180054870A (ko) 2018-05-24
TW202110435A (zh) 2021-03-16
CN108135883B (zh) 2021-09-14
KR102000897B1 (ko) 2019-07-16

Similar Documents

Publication Publication Date Title
US11007152B2 (en) Pharmaceutical composition comprising amorphous lenalidomide and an antioxidant
JP6168673B2 (ja) アリールアルキルアミン化合物含有医薬組成物
ES2522297T3 (es) Una forma farmacéutica que contiene dos principios activos farmacéuticos en diferentes formas físicas
JP2017071605A5 (enExample)
KR20240104205A (ko) 의약품
US10583087B2 (en) Pharmaceutical composition for oral administration
JP5490347B2 (ja) 経口投与用製剤
KR102488488B1 (ko) 아릴알킬아민 화합물 함유 의약 조성물
JP2013216701A (ja) 経口投与用製剤
KR20210096162A (ko) 의약 조성물
US9775832B2 (en) Pharmaceutical composition for oral administration
WO2022095913A1 (en) Solid formulation
JP6336651B1 (ja) 化学的安定性が改善されたエソメプラゾール塩を含有する錠剤
JP2022151564A (ja) 薬効成分としてビルダグリプチンおよびメトホルミンを含む錠剤
JP2022151841A (ja) ビルダグリプチン製剤
JP2015193611A (ja) 安定な固形医薬組成物
HK40058353A (en) Pharmaceutical composition
JP2012012411A (ja) 経口投与用製剤
JP2012041290A (ja) ラフチジン含有固形製剤
JP2013119540A (ja) 固形医薬組成物およびその製造法

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170117

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170608

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170623

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170623

R150 Certificate of patent or registration of utility model

Ref document number: 6168673

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250